<DOC>
	<DOC>NCT00148018</DOC>
	<brief_summary>The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.</brief_summary>
	<brief_title>Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma</brief_title>
	<detailed_description>The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line. In addition, several studies in heavily pretreated patients with lymphoma showed also promising results.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Hodgkin's lymphoma Second or higher relapse (first relapse if highdose chemotherapy not possible) Age &gt;/= 18 years No major organ dysfunction or intercurrent disorder Written informed consent Pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Hodgkin disease</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Relapse</keyword>
	<keyword>Lymphoma</keyword>
</DOC>